An Open-Label Study to Evaluate the Safety, Antiviral Activity and Pharmacokinetics of Direct-Acting Antiviral Agent (DAA) Treatment in Combination With Peginterferon α-2a and Ribavirin (pegIFN/RBV) in Chronic Hepatitis C Virus (HCV) Infected Subjects Who Have Experienced Virologic Failure in a Previous AbbVie or Abbott DAA Combination Study

Trial Profile

An Open-Label Study to Evaluate the Safety, Antiviral Activity and Pharmacokinetics of Direct-Acting Antiviral Agent (DAA) Treatment in Combination With Peginterferon α-2a and Ribavirin (pegIFN/RBV) in Chronic Hepatitis C Virus (HCV) Infected Subjects Who Have Experienced Virologic Failure in a Previous AbbVie or Abbott DAA Combination Study

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Jul 2017

At a glance

  • Drugs Ombitasvir (Primary) ; Paritaprevir (Primary) ; Peginterferon alfa-2a; Ribavirin; Ritonavir
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Sponsors Abbott Laboratories; AbbVie; GlaxoSmithKline
  • Most Recent Events

    • 12 May 2017 Status changed from active, no longer recruiting to completed.
    • 12 Jan 2017 Planned number of patients changed from 93 to 35.
    • 12 Jan 2017 Planned primary completion date changed from 1 Oct 2016 to 1 May 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top